6. Bibliografia

  1. Sheridan DJ (2000) Drug-induced proarrhythmic effects: assessment of changes in QT interval. Br J Clin Pharmacol 50: 297-302
  2. Bonate PL, Russell T (1999) Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective. J Clin Pharmacol 39: 349-358
  3. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R (2000) The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 21: 1216-1231
  4. Tamargo J (2000) Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol 83: 1-19
  5. Zhang MQ (1997) Chemistry underlying the cardiotoxicity of antihistamines. Current Medicinal Chemistry 4: 171-184
  6. De Ponti F, Poluzzi E, Montanaro N (2000) QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 56: 1-18
  7. Woosley R, Darrow WR (1994) Analysis of potential adverse drug reactions-a case of mistaken identity. Am J Cardiol 74: 208-209
  8. Shivkumar K (2000) Images in cardiovascular medicine. Labile repolarization from "cell to bedside". Circulation 102: 817-818
  9. Anon. (1997) European Agency for the Evaluation of Medicinal Products (EMEA): Committee for Proprietary Medicinal Products (CMPMP) (1997): Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products.
  10. Yap YG, Camm J (2000) Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation. BMJ 320: 1158-1159
  11. Drici MD, Barhanin J (2000) Cardiac K+ channels and drug-acquired long QT syndrome. Therapie 55: 185-193
  12. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, Schwartz K, Coumel P, Guicheney P (1997) KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 96: 2778-2781
  13. Priori SG, Napolitano C, Schwartz PJ (1999) Low penetrance in the long-QT syndrome: clinical impact. Circulation 99: 529-533
  14. Chiang CE, Roden DM (2000) The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 36: 1-12
  15. Kubota T, Shimizu W, Kamakura S, Horie M (2000) Hypokalemia-induced long QT syndrome with an underlying novel missense mutation in S4-S5 linker of KCNQ1. J Cardiovasc Electrophysiol 11: 1048-1054
  16. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA (1999) MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97: 175-187
  17. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George ALJ, Goldstein SA (2000) A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 97: 10613-10618
  18. De Ponti F, Poluzzi E, Montanaro N, Ferguson J (2000) QTc and psychotropic drugs. Lancet 356: 75-76
  19. De Ponti F, Poluzzi E, Ferguson J, Bergman U., Bjerrum L., McManus P., Sanz E., Schbert I:, Montanaro N (2000) Exposure to non-cardiac QT-prolonging drugs in the community: comparison among seven countries. Pharmacoepidemiology and Drug Safety 9 (suppl 1): S16
  20. Bonate PL, Russell T (1999) Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective. J Clin Pharmacol 39: 349-358
  21. Crumb W., Cavero I. (1999) QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharmaceutical Science and Technology Today 2: 270-280
  22. Champeroux P, Martel E, Vannier C, Blanc V, Leguennec JY, Fowler J, Richard S (2000) The preclinical assessment of the risk for QT interval prolongation. Therapie 55: 101-109
  23. Kriwisky M, Perry GY, Tarchitsky D, Gutman Y, Kishon Y (1990) Haloperidol-induced torsades de pointes. Chest 98: 482-484
  24. Jackson T, Ditmanson L, Phibbs B (1997) Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 157: 2013-2015
  25. Lawrence KR, Nasraway SA (1997) Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 17: 531-537
  26. Fayer SA (1986) Torsades de pointes ventricular tachyarrhythmia associated with haloperidol. J Clin Psychopharmacol 6: 375-376
  27. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM (1993) Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 119: 391-394
  28. Metzger E, Friedman R (1993) Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 13: 128-132
  29. Sharma ND, Rosman HS, Padhi ID, Tisdale JE (1998) Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 81: 238-240
  30. O'Brien J.M., Rockwood R.P., Suh K.I. (1999) Haloperidol-induced torsade de pointes. Ann Pharmacother 33: 1046-1050
  31. Perrault LP, Denault AY, Carrier M, Cartier R, Belisle S (2000) Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anaesth 47: 251-254
  32. Douglas PH, Block PC (2000) Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. Catheter Cardiovasc Interv 50: 352-355
  33. Kundu S, Williams SR, Nordt SP, Clark RF (1997) Clarithromycin-induced ventricular tachycardia. Ann Emerg Med 30: 542-544
  34. Lee KL, Jim MH, Tang SC, Tai YT (1998) QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med 104: 395-396
  35. van Haarst AD, van 't K, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, Coene MC, Cohen AF (1998) The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 64: 542-546
  36. Kitayama H, Kiuchi K, Nejima J, Katoh T, Takano T, Hayakawa H (1999) Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease [In Process Citation]. Eur J Clin Pharmacol 55: 259-262
  37. Cointe R, Dussarat GV, Mafart B, Bru P, Levy S (1989) Effet arythmogène des antidépresseurs. Mise en évidence par la stimulation ventriculaire programmée. Arch Mal Coeur Vaiss 82: 401-404
  38. Ochiai H, Kashiwagi M, Usui T, Oyama Y, Tokita Y, Ishikawa T (1990) Torsade de Pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: report of a case. Kokyu To Junkan 38: 819-822
  39. Oberg KC, Bauman JL (1995) QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 15: 687-692
  40. Orban Z, MacDonald LL, Peters MA, Guslits B (1995) Erythromycin-induced cardiac toxicity. Am J Cardiol 75: 859-861
  41. Katapadi K, Kostandy G, Katapadi M, Hussain KM, Schifter D (1997) A review of erythromycin-induced malignant tachyarrhythmia-torsade de pointes. A case report. Angiology 48: 821-826
  42. Gitler B, Berger LS, Buffa SD (1994) Torsades de pointes induced by erythromycin. Chest 105: 368-372
  43. Mishra A, Friedman HS, Sinha AK (1999) The effects of erythromycin on the electrocardiogram. Chest 115: 983-986
  44. Tschida SJ, Guay DR, Straka RJ, Hoey LL, Johanning R, Vance BK (1996) QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 16: 663-674
  45. Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J (1994) Droperidol causes a dose-dependent prolongation of the QT interval. Anesthesia Analgesia 79: 983-986
  46. Michalets EL, Smith LK, Van-Tassel ED (1998) Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 32: 761-765
  47. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355: 1048-1052
  48. Stramba Badiale M, Guffanti S, Porta N, Frediani M, Beria G, Colnaghi C (1993) QT interval prolongation and cardiac arrest during antibiotic therapy with spiramycin in a newborn infant. Am Heart J 126: 740-742
  49. Stramba Badiale M, Nador F, Porta N, Guffanti S, Frediani M, Colnaghi C, Grancini F, Motta G, Carnelli V, Schwartz P (1997) QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am Heart J 133: 108-111
  50. Kränhenbühl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ (1995) Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 309: 315-316
  51. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie JW (1987) ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 144: 673-675
  52. Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, Mahal SK, Babb VJ (2000) Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 20: 317-324
  53. Desta Z, Kerbusch T, Flockhart DA (1999) Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 65: 10-20
  54. Gajwani P, Pozuelo L, Tesar GE (2000) QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 41: 63-65
  55. Toivonen L, Viitasalo M, Siikamaki H, Raatikka M, Pohjola SS (1994) Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol 17: 403-404
  56. Wesche DL, Schuster BG, Wang WX, Woosley RL (2000) Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 67: 521-529
  57. Monlun E, Pillet O, Cochard JF, Favarel GJ, le-Bras M (1993) Prolonged QT interval with halofantrine. Lancet 341: 1541-1542
  58. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ (1993) Cardiac effects of antimalarial treatment with halofantrine. Lancet 341: 1054-1056
  59. Karbwang J, Na BK, Bunnag D, Harinasuta T, Laothavorn P (1993) Cardiac effect of halofantrine. Lancet 342: 501
  60. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 124: 168-175
  61. Pezawas L, Quiner S, Moertl D, Tauscher J, Barnas C, Kufferle B, Wolf R, Kasper S (2000) Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. Int Clin Psychopharmacol 15: 207-214
  62. Padmaja UK, Adhikari P, Periera P (1999) Experience with quinine in falciparum malaria. Indian J Med Sci 53: 153-157
  63. Claessen FA, van-Boxtel CJ, Perenboom RM, Tange RA, Wetsteijn JC, Kager PA (1998) Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. Trop Med Int Health 3: 482-489
  64. Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH (1996) Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 60: 543-553
  65. Kiriike N, Maeda Y, Nishiwaki S, Izumiya Y, Katahara S, Mui K, Kawakita Y, Nishikimi T, Takeuchi K, Takeda T (1987) Iatrogenic torsade de pointes induced by thioridazine. Biol Psychiatry 22: 99-103
  66. Bertino JJ, Fish D (2000) The safety profile of the fluoroquinolones. Clin Ther 22: 798-817
  67. Lode H, Vogel F, Elies W (1999) Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance. Clin Ther 21: 61-74
  68. Van de Merwe TJ, Silverstone T, Ankier SI (1984) Electrophysiological and haemodynamic changes with trazodone, amitriptyline and placebo in depressed out-patients. Curr Med Res Opin 9: 339-352
  69. Dorsey ST, Biblo LA (2000) Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 18: 227-229
  70. Manikoth P, Subramanyan R, Menon S, Al Khusaiby SM (1999) A child with cardiac arrhythmia and convulsions. Lancet 354: 2046
  71. Samaha FF (1999) QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 107: 528-529
  72. Ball P, Mandell L, Niki Y, Tillotson G (1999) Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 21: 407-421
  73. Leonard HL, Meyer MC, Swedo SE, Richter D, Hamburger SD, Allen AJ, Rapoport JL, Tucker E (1995) Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry 34: 1460-1468
  74. Wagner KD, Fershtman M (1993) Potential mechanism of desipramine-related sudden death in children. Psychosomatics 34: 80-83
  75. Demolis JL, Charransol A, Funck-Brentano C, Jaillon P (1996) Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol 41: 499-503
  76. Jaillon P, Morganroth J, Brumpt I, Talbot G (1996) Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 37 Suppl A: 161-167
  77. Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH (1999) The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. Clin Ther 21: 1171-1181
  78. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C (1996) Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest 110: 1499-1506
  79. Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K (1982) Doxepin induced torsade de pointes. Pacing Clin Electrophysiol 5: 873-877
  80. Baker B, Dorian P, Sandor P, Shapiro C, Schell C, Mitchell J, Irvine MJ (1997) Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 17: 15-21
  81. Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI (1998) Proarrhythmia associated with cisapride in children. Pediatrics 101: 1053-1056
  82. Benatar A, Feenstra A, Decraene T, Vandenplas Y (1999) Cisapride and proarrhythmia in childhood. Pediatrics 103: 856-857
  83. Khongphatthanayothin A, Lane J, Thomas D, Yen L, Chang D, Bubolz B (1998) Effects of cisapride on QT interval in children. J Pediatr 133: 51-56
  84. Khoshoo V, Edell D, Clarke R (2000) Effect of cisapride on the QT interval in infants with gastroesophageal reflux. Pediatrics 105: E24
  85. Bernardini S, Semama DS, Huet F, Sgro C, Gouyon JB (1997) Effects of cisapride on QTc interval in neonates. Arch Dis Child Fetal Neonatal Ed 77: F241-F243
  86. Tutar HE, Kansu A, Kalayci AG, Girgin N, Atalay S, Imamoglu A (2000) Effects of cisapride on ventricular repolarization in children. Acta Paediatr 89: 820-823
  87. de Abajo FJ, Rodriguez LA (1999) Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol 47: 307-313
  88. Sakemi H, VanNatta B (1993) Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval. Am Heart J 125: 1436-1438
  89. Hsieh MH, Chen SA, Chiang CE, Tai CT, Lee SH, Wen ZC, Chang MS (1996) Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Int J Cardiol 54: 85-88
  90. Tsai WC, Tsai LM, Chen JH (1997) Combined use of astemizole and ketoconazole resulting in torsade de pointes. J Formos Med Assoc 96: 144-146
  91. Moss AJ, Chaikin P, Garcia JD, Gillen M, Roberts DJ, Morganroth J (1999) A review of the cardiac systemic side-effects of antihistamines: ebastine. Clin Exp Allergy 29 Suppl 3: 200-205
  92. Paserchia LA, Hewett J, Woosley RL (1994) Effect of ketoconazole on QTc. Clin Pharmacol Ther 55: 146
  93. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moye L (1994) Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine [see comments]. Am J Cardiol 73: 346-352
  94. Khalifa M, Drolet B, Daleau P, Lefez C, Gilbert M, Plante S, O'Hara GE, Gleeton O, Hamelin BA, Turgeon J (1999) Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. J Pharmacol Exp Ther 288: 858-865
  95. Gonzalez A, Sager PT, Akil B, Rahimtoola SH, Bhandari AK (1991) Pentamidine-induced torsade de pointes. Am Heart J 122: 1489-1492
  96. Stein KM, Haronian H, Mensah GA, Acosta A, Jacobs J, Kligfield P (1990) Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am J Cardiol 66: 888-889
  97. Bibler MR, Chou TC, Toltzis RJ, Wade PA (1988) Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity. Chest 94: 1303-1306
  98. Lindsay JJ, Smith MA, Light JA (1990) Torsades de pointes associated with antimicrobial therapy for pneumonia. Chest 98: 222-223
  99. Girgis I, Gualberti J, Langan L, Malek S, Mustaciuolo V, Costantino T, McGinn TG (1997) A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 112: 646-653
  100. Woosley RL, Chen Y, Freiman JP, Gillis RA (1993) Mechanism of the cardiotoxic actions of terfenadine. JAMA 269: 1532-1536
  101. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena-LR J (1990) Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788-2790
  102. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, Ruskin J, Moye L (1996) Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 131: 472-480
  103. Reinoehl J, Frankovich D, Machado C, Kawasaki R, Baga JJ, Pires LA, Steinman RT, Fromm BS, Lehmann MH (1996) Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 131: 1184-1191
  104. Dujovne CA, Atkins F, Wong B, DeCoursey S, Krehbiel P, Chernoff SB (1984) Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol 26: 735-739
  105. Romics L, Littmann L, Laszlo Z, Fenyvesi T (1988) The effects of probucol on QT/QS2 relation and systolic time intervals. Int J Cardiol 19: 303-308
  106. Ohya Y, Kumamoto K, Abe I, Tsubota Y, Fujishima M (1993) Factors related to QT interval prolongation during probucol treatment. Eur J Clin Pharmacol 45: 47-52
  107. Tamura M, Ueki Y, Ohtsuka E, Oribe M, Seita M, Oribe K, Ito M (1994) Probucol-induced QT prolongation and syncope. Jpn Circ J 58: 374-377
  108. Johnson MC, So S, Marsh JW, Murphy AM (1992) QT prolongation and Torsades de Pointes after administration of FK506. Transplantation 53: 929-930
  109. Hodak SP, Moubarak JB, Rodriguez I, Gelfand MC, Alijani MR, Tracy CM (1998) QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation 66: 535-537
  110. Sawabe T, Mizuno S, Gondo H, Maruyama T, Niho Y (1997) Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. Transplantation 64: 182-183
  111. Calandra S (1998) Sinus arrest during tacrolimus treatment: was the QT interval prolonged? Transplantation 66: 402-404
  112. Coumel P (1992) Safety of bepridil: from review of the European data. Am J Cardiol 69: 75D-78D
  113. Viallon A, Laporte-Simitsidis S, Pouzet V, Venet C, Tardy B, Zeni F, Bertrand JC (2000) Bépridil: intérêt du dosage sérique dans la surveillance du traitement. Presse Med 29: 645-647
  114. Connolly MJ, Astridge PS, White EG, Morley CA, Cowan JC (1991) Torsades de pointes ventricular tachycardia and terodiline. Lancet 338: 344-345
  115. Stewart DA, Taylor J, Ghosh S, Macphee GJ, Abdullah I, McLenachan JM, Stott DJ (1992) Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 42: 577-580
  116. Hartigan-Go K, Bateman DN, Daly AK, Thomas SH (1996) Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 60: 89-98
  117. Thomas SH, Higham PD, Hartigan GK, Kamali F, Wood P, Campbell RW, Ford GA (1995) Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 74: 53-56
  118. Kawade M, Ohe T, Kamiya T (1995) Provocative testing and drug response in a patient with the long QT syndrome. Br Heart J 74: 67-70
  119. Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF (1995) A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 35: 705-712
  120. Shimizu W, Ohe T, Kurita T, Takaki H, Aihara N, Kamakura S, Matsuhisa M, Shimomura K (1991) Early afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation 84: 1915-1923
  121. Wiener I, Rubin DA, Martinez E, Postman J, Herman MV (1981) QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration. Mt Sinai J Med 48: 53-55
  122. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T (1987) QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 59: 376-377
  123. Aldariz AE, Romero H, Baroni M, Baglivo H, Esper RJ (1986) QT prolongation and torsade de pointes ventricular tachycardia produced by Ketanserin. Pacing Clin Electrophysiol 9: 836-841
  124. Zehender M, Meinertz T, Hohnloser S, Geibel A, Hartung J, Seiler KU, Just H (1989) Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Am J Cardiol 63: 826-832
  125. Cameron HA, Waller PC, Ramsay LE (1988) Prolongation of the QT interval by ketanserin. Postgrad Med J 64: 112-117
  126. Nademanee K, Lockhart E, Pruitt C, Singh BN (1987) Cardiac electrophysiologic effects of intravenous ketanserin in humans. J Cardiovasc Pharmacol 10 Suppl 3: S81-S85
  127. du Souich P., Besner JG, Clozel JP, Welker HA, Lefebvre M, Caille G (2000) Nonlinear kinetics and pharmacologic response to mibefradil. Clin Pharmacol Ther 67: 249-257
  128. Murakawa Y, Yamashita T, Ajiki K, Sezaki K, Omata M (1998) Ostensible day-night difference of QT prolongation during long-term treatment with antiarrhythmic drugs: reappraisal of the law of "regression to the mean". J Cardiovasc Pharmacol 32: 62-65
Precedente
Indice